Peter Attia· MD
how do we go and target other things upstream that might be more amenable to giving us sort of more of this dream molecule of a pan mTORC1 inhibitor and no mTORC2 activity?
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
how do we go and target other things upstream that might be more amenable to giving us sort of more of this dream molecule of a pan mTORC1 inhibitor and no mTORC2 activity?
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.